Entera Bio (NASDAQ:ENTX) Stock Gets Downgrade from Wall Street Zen

Entera Bio (NASDAQ:ENTX) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald initiated coverage on Entera Bio in a research note on Tuesday, September 22nd. They set an “overweight” rating for the company. Leerink Partners assumed coverage on Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, October 15th. UBS Group set a $9.00 price target on Entera Bio in a research report on Friday, September 18th. Finally, Lifesci Capital assumed coverage on shares of Entera Bio in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.60.

Entera Bio Stock Performance

Shares of ENTX opened at $3.14 on Friday. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20. The firm has a fifty day moving average of $2.88 and a 200-day moving average of $1.95. The company has a market cap of $546.11 million, a price-to-earnings ratio of -8.97 and a beta of 1.48.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Analysts predict that Entera Bio will post -0.40 EPS for the current year.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP increased its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned 0.42% of Entera Bio worth $228,000 at the end of the most recent quarter. Institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.